J. Costantino

发表

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

M. Cronin, S. Paik, G. Tang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

C K Redmond, B Fisher, C. Redmond, 1999, Journal of the National Cancer Institute.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Abstract S1-10: Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28

T. Julian, S. Paik, G. Tang, 2012 .

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Gideon Blumenthal, Nina Ditsch, David Cameron, 2014, The Lancet.

Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies

D. Schaid, G. Jenkins, R. Weinshilboum, 2012, Genetic epidemiology.

Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.

T. Julian, J. Costantino, N. Wolmark, 2007, The Lancet. Oncology.

Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.

T. Julian, J. Costantino, N. Wolmark, 2010, The Lancet. Oncology.

A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.

C. Redmond, J. Costantino, D. Wickerham, 1989, The New England journal of medicine.

Morbidity results from the NSABP B‐32 trial comparing sentinel lymph node dissection versus axillary dissection

Norman Wolmark, Takamaru Ashikaga, T. Julian, 2010, Journal of surgical oncology.

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Debora Fumagalli, Norman Wolmark, Soonmyung Paik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2–Positive Breast Cancer: Analysis of the NSABP B-31 Trial

S. Paik, J. Costantino, C. Geyer, 2017, JAMA oncology.

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

B Fisher, J Costantino, C. Redmond, 1996, Journal of the National Cancer Institute.

Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.

J. Costantino, D. Wickerham, N. Wolmark, 2005, American journal of obstetrics and gynecology.

Effects of tamoxifen on benign breast disease in women at high risk for breast cancer.

S. Paik, J. Costantino, D. Wickerham, 2003, Journal of the National Cancer Institute.

Coronary heart disease mortality and adjuvant tamoxifen therapy.

L. Kuller, J. Costantino, B. Fisher, 1997, Journal of the National Cancer Institute.

Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients.

C. Redmond, C. Polychronakos, J. Costantino, 1990, Journal of the National Cancer Institute.

Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and

C. Redmond, J. Costantino, D. Wickerham, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Occupationally Related Cancer Risk Among Coke Oven Workers: 30 Years of Follow-Up

C. Redmond, J. Costantino, A. Bearden, 1995, Journal of occupational and environmental medicine.

Erratum to: 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1

J. Costantino, P. Ganz, P. Goodwin, 2012, Breast Cancer Research and Treatment.

25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1

J. Costantino, P. Ganz, P. Goodwin, 2012, Breast Cancer Research and Treatment.

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

T. Wilt, B. Kramer, P. Schellhammer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view.

J. Costantino, V. Vogel, 2001, Clinical breast cancer.

Computations of adjusted rates and lifetime risks from occupational cohort data: a program package using FORTRAN and GLIM.

M. H. Dong, C. Redmond, J. Costantino, 1991, Computers and biomedical research, an international journal.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Cognitive Factors Associated with Adherence to Oral Antiestrogen Therapy: Results from the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Study

K. Sink, H. Atkinson, S. Rapp, 2013, Cancer Prevention Research.

Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.

S. Paik, Chungyeul Kim, J. Costantino, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial

J. Costantino, N. Wolmark, S. Swain, 2008, Breast Cancer Research and Treatment.

Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B‐17. Intraductal carcinoma (ductal carcinoma in situ)

Joseph Costantino, C. Redmond, J. Costantino, 1995, Cancer.

Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31

S. Paik, Chungyeul Kim, J. Costantino, 2007 .

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial

S. Reis, W. McCaskill-Stevens, S. Lippman, 2006 .

Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07.

J. Kopec, D. Cella, J. Costantino, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

T. Julian, J. Costantino, N. Wolmark, 2016, The Lancet.

OT2-06-02: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women with Stage 0, 1, or 2 Breast Cancer: NSABP B-39/RTOG 0413.

W. Curran, T. Julian, F. Vicini, 2011 .

Conclusions: Considerations regarding SERMs.

J. Costantino, B. Dunn, S. Sherman, 2006, Annals of the New York Academy of Sciences.

Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches.

T. Julian, J. Costantino, N. Wolmark, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefit/Risk Assessment in Prevention Trials

J. Costantino, 2005 .

Benefit/Risk Assessment in Prevention Trials

J. Costantino, 2005 .

The effect of obliterative bronchiolitis on breathing pattern during exercise in recipients of heart-lung transplants.

B. Griffith, J. Costantino, F. Sciurba, 1991, The American review of respiratory disease.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.

S. Paik, G. Tang, J. Costantino, 2015, The Lancet. Oncology.

Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer.

W. Curran, M. Scheier, H. Kuerer, 2019, Journal of Clinical Oncology.

Mucocele-like Lesions and Mucinous Carcinoma of the Breast

J. Costantino, E. Fisher, A. Palekar, 1994 .

Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.

J. Garber, J. Costantino, D. Wickerham, 2006, Journal of the National Cancer Institute.

Pathologic findings from the national surgical adjuvant breast project (NSABP) protocol B‐17: Intraductal carcinoma (ductal carcinoma in situ)

J. Costantino, E. Mamounas, B. Fisher, 2006 .

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

C. Redmond, J. Costantino, D. Wickerham, 1994, Journal of the National Cancer Institute.

Abstract S2-05: 10-yr follow-up results of occult detected sentinel node disease: NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients

T. Julian, J. Costantino, N. Wolmark, 2013 .

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

M. Buyse, J. Mackey, N. Robert, 2013 .

Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2015 .

NSABP B-47: A randomized phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer.

S. Paik, J. Costantino, C. Geyer, 2013 .

Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials

Erin E. Carlson, D. Schaid, Yusuke Nakamura, 2011, Clinical Cancer Research.

Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).

L. Ford, J. Costantino, D. Wickerham, 2011, American journal of obstetrics and gynecology.

Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

T. Julian, I. Nagtegaal, S. Paik, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

W. McCaskill-Stevens, J. Costantino, D. Wickerham, 2010, Journal of the National Cancer Institute. Monographs.

Quality assurance of pathology in clinical trials: The national surgical adjuvant breast and bowel project experience

J. Costantino, E. Fisher, J. Costantino, 1994, Cancer.

Long-term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24

T. Julian, J. Costantino, N. Wolmark, 2007 .

Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.

T. Julian, J. Costantino, N. Wolmark, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Primary results , NSABP B-35 / NRG Oncology : A clinical trial of anastrozole vs tamoxifen in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy A randomized clinical trial

T. Julian, J. Costantino, R. Margolese, 2016 .

The impact of systemic therapy following ductal carcinoma in situ.

J. Costantino, S. Swain, J. Eng-Wong, 2010, Journal of the National Cancer Institute. Monographs.

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43

W. McCaskill-Stevens, T. Julian, J. Costantino, 2013, Breast Cancer Research and Treatment.

Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

T. Julian, J. Costantino, N. Wolmark, 2011, Journal of the National Cancer Institute.

Is boost therapy necessary in the treatment of DCIS

T. Julian, F. Vicini, J. Costantino, 2008 .

Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary.

T. Wilt, B. Kramer, P. Schellhammer, 2009, Journal of oncology practice.

Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

T. Wilt, B. Kramer, P. Schellhammer, 2009, The Journal of urology.

Use of 5- (cid:1) -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/ American Urological Association 2008 Clinical Practice Guideline

T. Wilt, B. Kramer, M. Somerfield, 2009 .

Benefit/Risk Assessment in Prevention Trials

J. Costantino, 2005 .

Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients.

T. Julian, J. Costantino, N. Wolmark, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients.

T. Julian, J. Costantino, N. Wolmark, 2010 .

Prognosis among African‐American women and white women with lymph node negative breast carcinoma

C. Redmond, B. Edwards, J. Costantino, 1997, Cancer.

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.

S. Paik, G. Tang, J. Costantino, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of tamoxifen and uterine sarcoma.

J. Bryant, J. Costantino, D. Wickerham, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer.

J. Costantino, N. Wolmark, R. Livingston, 2009 .

Tamoxifen and Cardiac Risk Factors in Healthy Women Suggestion of an Anti-inflammatory Effect

John D. Roberts, J. Costantino, D. Krag, 2001 .

Tamoxifen and Cardiac Risk Factors in Healthy Women: Suggestion of an Anti-inflammatory Effect

John D. Roberts, J. Costantino, D. Krag, 2001, Arteriosclerosis, thrombosis, and vascular biology.

Evidence of an altered pattern of breathing during exercise in recipients of heart-lung transplants.

B. Griffith, J. Costantino, F. Sciurba, 1988, The New England journal of medicine.

Re: Risk/benefit assessment of tamoxifen to prevent breast cancer-still a work in progress?

R. Croyle, M. Gail, J. Bryant, 2000, Journal of the National Cancer Institute.

Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial.

E. Perez, J. Costantino, C. Geyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chromosomal aberrations and sister-chromatid exchanges in lymphocytes from coke oven workers.

C. Redmond, M. Bender, J. Costantino, 1988, Mutation research.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

Mike Clarke, Yasuo Ohashi, Michael Gnant, 2018, The Lancet. Oncology.

OlympiA: A randomized phase III trial of olaparib as adjuvant therapy in patients with high-risk HER2-negative breast cancer (BC) and a germline BRCA1/2 mutation (gBRCAm).

R. Gelber, A. Tutt, J. Garber, 2015 .

Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer.

B Fisher, J Costantino, C. Redmond, 1993, The New England journal of medicine.

Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial

John D. Roberts, J. Costantino, D. Wickerham, 2003, British journal of haematology.

A randomized, prospective evaluation of noninvasive ventilation for acute respiratory failure.

J. Costantino, R. Rogers, F. Sciurba, 2000, American journal of respiratory and critical care medicine.

Split-night studies for the diagnosis and treatment of sleep-disordered breathing.

J. Costantino, P. Strollo, M. Sanders, 1996, Sleep.

Prescription of positive airway pressure for sleep apnea on the basis of a partial-night trial.

J. Costantino, M. Sanders, S. Orris, 1993, Sleep.

Polysomnography early after uvulopalatopharyngoplasty as a predictor of late postoperative results.

J. Costantino, M. Sanders, J. T. Johnson, 1990, Chest.

Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28.

T. Julian, S. Paik, G. Tang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Five year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC)->paclitaxel (T) vs. AC->T with trastuzumab (H)

J. Costantino, N. Wolmark, S. Swain, 2006 .

Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29

K. Gelmon, J. Costantino, N. Wolmark, 2015, Breast Cancer Research and Treatment.

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

Joseph P. Costantino, Stewart J. Anderson, Norman Wolmark, 2011, Breast Cancer Research and Treatment.

Final updated results of the NRG Oncology/NSABP Protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer.

S. Reis, W. McCaskill-Stevens, L. Ford, 2015 .

Issues and findings in the evaluation of occupational risk among women high nickel alloys workers.

C. Redmond, J. Costantino, V. Arena, 1999, American journal of industrial medicine.

IS TAMOXIFEN A RISK FACTOR FOR RETINAL VASO-OCCLUSIVE DISEASE?

J. Costantino, D. Wickerham, N. Wolmark, 2005, Retina.

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

R. Gelber, M. Piccart, S. Lakhani, 2021, The New England journal of medicine.

Abstract GS4-04: Primary results of NSABP B-39/RTOG 0413 (NRG Oncology): A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer

W. Curran, M. Scheier, G. Gustafson, 2019, General Session Abstracts.

Early toxicity results with 3D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial.

W. Curran, T. Julian, F. Vicini, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.

S. Paik, G. Tang, S. Shak, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of hormonal treatments on quality of life of patients with metastatic breast cancer.

J. Costantino, 2002, Clinical therapeutics.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Norman Wolmark, Scott M Lippman, S. Reis, 2006, JAMA.

Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.

J. Costantino, C. Geyer, D. Wickerham, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.

A. Taghian, J. Costantino, N. Wolmark, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)

P. Fasching, C. Perou, J. Bergh, 2012 .

Survival after IBTR in NSABP Node Negative Protocols B-13, B-14, B-19, B-20 and B-23

J. Costantino, N. Wolmark, E. Mamounas, 2005 .

Response to "Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation" (Int J Radiat Oncol Biol Phys 2010;76:71-78) and "Toxicity of three-dimensional conformal radiotherapy for accelerated partial bre

W. Curran, T. Julian, F. Vicini, 2010, International journal of radiation oncology, biology, physics.

Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32.

T. Julian, J. Kopec, J. Costantino, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer

Joseph P. Costantino, V. Craig Jordan, Victor G. Vogel, 2010, Cancer Prevention Research.

Using alternative comparison populations to assess occupation-related mortality risk. Results for the high nickel alloys workers cohort.

J. Trauth, C. Redmond, J. Costantino, 1998, Journal of occupational and environmental medicine.

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

A. LaCroix, S. Cummings, J. Cuzick, 2013, The Lancet.

Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17.

J. Costantino, D. Wickerham, N. Wolmark, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

M. Gail, W. McCaskill-Stevens, G. Anderson, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

S. Paik, J. Costantino, C. Geyer, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Bingshu E. Chen, D. Berry, P. Fasching, 2019, The Lancet.

Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.

T. Walsh, M. King, L. Ford, 2001, JAMA.

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.

S. Paik, J. Costantino, C. Geyer, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

T. Julian, S. Paik, G. Tang, 2018, Breast Cancer Research and Treatment.

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

Sally Hunsberger, R. Gray, R. Gelber, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.

Daoud M. Meerzaman, K. Buetow, J. M. Kelley, 2010, International journal of molecular epidemiology and genetics.

Original Article Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial

Daoud M. Meerzaman, K. Buetow, J. M. Kelley, 2010 .

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

J Benichou, M H Gail, C K Redmond, 1999, Journal of the National Cancer Institute.

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

M H Gail, R. Croyle, M. Gail, 1999, Journal of the National Cancer Institute.

Flow cytometric DNA analysis of Neuroblastoma and Ganglioneuroma. A 10‐year retrospective study

J. Costantino, M. Roederer, R. Murphy, 1988, Cancer.

Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0)

J. Costantino, N. Wolmark, B. Fisher, 2007, Cancer.

Projecting individualized absolute invasive breast cancer risk in African American women.

Melissa Bondy, Giske Ursin, Mitchell H Gail, 2007, Journal of the National Cancer Institute.

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

J. Costantino, D. Wickerham, N. Wolmark, 2006, JAMA.

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

E. Perez, J. Costantino, C. Geyer, 2010, The New England journal of medicine.

Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.

S. Paik, G. Tang, J. Costantino, 2013, The Lancet. Oncology.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

L. Ford, J. Costantino, D. Wickerham, 2005, Journal of the National Cancer Institute.

Multivariate predictors of failed prehospital endotracheal intubation.

Henry E. Wang, P. Paris, D. Yealy, 2003, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

Validating and improving models for projecting the absolute risk of breast cancer.

M H Gail, M. Gail, J. Costantino, 2001, Journal of the National Cancer Institute.

The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40

S. Paik, G. Tang, J. Costantino, 2017, Annals of Surgical Oncology.

Pathologic variables predictive of breast events in patients with ductal carcinoma in situ.

J. Costantino, D. Wickerham, N. Wolmark, 2007, American journal of clinical pathology.

S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen- receptor-positive breast cancer

J. Bryant, J. Costantino, B. Fisher, 2004, Breast Cancer Research and Treatment.

Lower-category benign breast disease and the risk of invasive breast cancer.

S. Paik, J. Costantino, D. Wickerham, 2004, Journal of the National Cancer Institute.

Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study.

J. Costantino, P. Ganz, R. Day, 2001, Journal of the National Cancer Institute.

J. Costantino, D. Wickerham, P. Ganz, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnosis of sleep-disordered breathing by half-night polysomnography.

J. Costantino, M. Sanders, J. Coates, 1991, The American review of respiratory disease.

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

G. Tang, J. Costantino, C. Geyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

J. Cuzick, J. Forbes, M. Dowsett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

James A Young, Norman Wolmark, Rita S Mehta, 2012, The New England journal of medicine.

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

T. Julian, S. Paik, G. Tang, 2017, Journal of the National Cancer Institute.

Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials

D. Ross, B. Ring, S. Paik, 2008, Clinical Cancer Research.

Is Sentinel Node Biopsy Necessary in Conservatively Treated DCIS?

T. Julian, J. Costantino, N. Wolmark, 2007, Annals of Surgical Oncology.

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.

E. Perez, R. Gelber, J. Costantino, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.

J. Costantino, C. Geyer, D. Wickerham, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial

W. Curran, M. Scheier, H. Kuerer, 2019, The Lancet.

Abstract 2837: A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer

J. Costantino, C. Geyer, D. Wickerham, 2015 .

Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women.

Mitchell H Gail, Regina G Ziegler, David Pee, 2011, Journal of the National Cancer Institute.

Accuracy of end-tidal and transcutaneous PCO2 monitoring during sleep.

J. Costantino, P. Strollo, M. Sanders, 1994, Chest.

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

Jong-Hyeon Jeong, Hanna Bandos, Debora Fumagalli, 2013, Journal of the National Cancer Institute.

Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial

A. Terracciano, S. Rapp, J. Costantino, 2013, Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.

Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab

Krishna R. Kalari, Erin E. Carlson, P. Fasching, 2018, Pharmacogenetics and genomics.

Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.

E. Perez, J. Costantino, C. Geyer, 2012, The Lancet. Oncology.

Long-term tamoxifen citrate use and potential ocular toxicity.

C. Redmond, J. Costantino, N. Wolmark, 1998, American journal of ophthalmology.

Cigarette Smoking, Physical Activity, and Alcohol Consumption as Predictors of Cancer Incidence among Women at High Risk of Breast Cancer in the NSABP P-1 Trial

J. Costantino, D. Wickerham, P. Ganz, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.

S. Reis, J. Costantino, D. Wickerham, 2001, Journal of the National Cancer Institute.

Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).

W. Willett, S. Cummings, M. Dowsett, 2006, Journal of the National Cancer Institute.

The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

T. Powles, S. Martino, J. Costantino, 2004, The oncologist.

EDITORIALS Validating and Improving Models for Projecting the Absolute Risk of Breast Cancer

M. Gail, J. Costantino, 2001 .

Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38

G. Tang, J. Costantino, C. Geyer, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Body Mass Index and the Risk for Developing Invasive Breast Cancer among High-Risk Women in NSABP P-1 and STAR Breast Cancer Prevention Trials

J. Cauley, J. Costantino, D. Wickerham, 2012, Cancer Prevention Research.

Statistical concepts and biomedical research.

C. Redmond, J. Costantino, K. Yu, 1996, Urologic oncology.

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

S. Paik, G. Tang, S. Shak, 2018, npj Breast Cancer.

Adequacy of prescribing positive airway pressure therapy by mask for sleep apnea on the basis of a partial-night trial.

J. Costantino, M. Sanders, S. Orris, 1993, The American review of respiratory disease.

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

T. Julian, J. Costantino, N. Wolmark, 2016, The Lancet.

Cigarette Smoking, Obesity, Physical Activity, and Alcohol Use As Predictors of Chemoprevention Adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial

W. Klein, J. Costantino, D. Wickerham, 2011, Cancer Prevention Research.

Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk.

Lewis H Kuller, L. Kuller, J. Costantino, 2004, American journal of physiology. Heart and circulatory physiology.

Response—blunting the counterpoint

J. Costantino, E. Mamounas, B. Fisher, 1995 .

Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer

D. Berry, E. Feuer, R. Gray, 2018, Journal of the National Cancer Institute.

The Landmark Surgical Trials of the National Surgical Adjuvant Breast and Bowel Project

T. Julian, J. Costantino, D. Wickerham, 2006, World Journal of Surgery.

Landmark proportional subdistribution hazards models for dynamic prediction of cumulative incidence functions

Qing Liu, Joseph P. Costantino, Chung-Chou H. Chang, 2019, Journal of the Royal Statistical Society: Series C (Applied Statistics).

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

C. Denkert, J. Costantino, C. Geyer, 2018 .

Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.

Erin E. Carlson, D. Schaid, Yusuke Nakamura, 2013, Cancer discovery.

Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF 423 Regulation of BRCA 1 Expression : Individualized Breast Cancer Prevention

Erin E. Carlson, D. Schaid, Yusuke Nakamura, 2013 .

Design and current status of the NSABP breast cancer prevention trial.

C. Redmond, J. Costantino, 1996, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Lower-Category Benign Breast Disease and the Risk of Invasive Breast Cancer

S. Paik, J. Costantino, D. Wickerham, 2004 .

The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.

T. Julian, N. Petrelli, S. Paik, 2008, Seminars in oncology.

Nonparametric Inference on Median Residual Life Function

Sin-Ho Jung, Jong-Hyeon Jeong, Sin-Ho Jung, 2008, Biometrics.

Adjuvant Chemotherapy for Locoregional Recurrent Breast Cancer

Joseph P. Costantino, Stewart J. Anderson, Norman Wolmark, 2011 .

A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37.

R. Gelber, M. Piccart, J. Costantino, 2008, Clinical breast cancer.

Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer

M. Cronin, S. Paik, G. Tang, 2005 .

National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.

J. Costantino, D. Wickerham, W. Cronin, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.

J. Costantino, D. Wickerham, N. Wolmark, 2002, Clinical breast cancer.

Methodological Issues in the Analysis of Quality of Life Data in Clinical Trials: Illustrations from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial

J. Costantino, P. Ganz, T. T. Have, 2002 .

Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial.

J. Costantino, P. Ganz, R. Day, 1998, Statistics in medicine.

Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.

J. Costantino, D. Wickerham, P. Ganz, 2016, Journal of the National Cancer Institute.

Factors associated with participant adherence in the NSABP Study of Tamoxifen and Raloxifene (STAR)

J. Costantino, D. Wickerham, N. Wolmark, 2008 .

Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women

D. Cella, J. Costantino, N. Wolmark, 2008, Breast Cancer Research and Treatment.

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-stage HER2-positive Breast Cancer.

S. Paik, J. Costantino, C. Geyer, 2019, Journal of the National Cancer Institute.

Long-Term Survival Results of Surgery Alone Versus Surgery Plus 5-Fluorouracil and Leucovorin for Stage II and Stage III Colon Cancer: Pooled Analysis of NSABP C-01 Through C-05. A Baseline from Which to Compare Modern Adjuvant Trials

N. Petrelli, J. Costantino, N. Wolmark, 2010, Annals of Surgical Oncology.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.

S. Paik, G. Tang, J. Costantino, 2016 .

Multistage modeling of lung cancer mortality among arsenic-exposed copper-smelter workers.

C. Redmond, J. Costantino, G. Marsh, 1989, Risk analysis : an official publication of the Society for Risk Analysis.

Baseline Mammographic Breast Density and the Risk of Invasive Breast Cancer in Postmenopausal Women Participating in the NSABP Study of Tamoxifen and Raloxifene (STAR)

J. Cauley, J. Costantino, D. Wickerham, 2012, Cancer Prevention Research.

Serum level changes after administration of a pharmacologic dose of beta-carotene.

C. Redmond, L. Begg, L. Kuller, 1988, The American journal of clinical nutrition.

Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer.

J. Costantino, J. Qin, Yu Shen, 2008, Journal of the National Cancer Institute.

S2-3: NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis.

J. Costantino, N. Wolmark, S. Swain, 2011 .

Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

J. Costantino, D. Wickerham, W. Cronin, 2002, Journal of the National Cancer Institute.

Breast cancer risk factors and mammographic breast density in women over age 70

L. Kuller, J. Cauley, J. Costantino, 2006, Breast Cancer Research and Treatment.

Challenges in Monitoring the Breast Cancer Prevention Trial

C. Redmond, J. Costantino, T. Colton, 2006 .

Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue.

S. Paik, J. Baker, D. Watson, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Application of Smoothing Methods to Evaluate Treatment-Prognostic Factor Interactions in Breast Cancer Data

J. Costantino, Jong-Hyeon Jeong, 2006, Cancer investigation.

Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach.

J. Cuzick, J. Forbes, M. Dowsett, 2010 .

Patient-reported neurotoxicity with FULV versus FLOX in patients with stage II or III carcinoma of the colon: Results of NSABP Protocol C-07.

J. Kopec, J. Costantino, N. Wolmark, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.

S. Paik, G. Tang, J. Costantino, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The use of tamoxifen and raloxifene for the prevention of breast cancer.

L. Ford, J. Costantino, D. Wickerham, 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors.

J. Costantino, T. Medsger, V. Steen, 1990, Annals of internal medicine.

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

S. Steinberg, E. Rutgers, E. Winer, 2018, The Lancet. Oncology.

Physiologic effects of oral supplemental feeding in malnourished patients with chronic obstructive pulmonary disease. A randomized control study.

J. Costantino, R. Rogers, M. Donahoe, 1992, The American review of respiratory disease.

Lipid levels in adults with cystic fibrosis.

J. Costantino, D. Orenstein, M. J. Slesinski, 1994, Journal of the American Dietetic Association.

Breathing during wakefulness and sleep after human heart-lung transplantation.

B. Griffith, J. Costantino, R. Rogers, 1989, The American review of respiratory disease.

Locoregional recurrence (LRR) after neoadjuvant chemotherapy (NAC): Pooled-analysis results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC).

J. Costantino, C. Geyer, N. Wolmark, 2014, Journal of Clinical Oncology.

Prevalence of thyroid antibodies among healthy middle-aged women. Findings from the thyroid study in healthy women.

L. Kuller, J. Costantino, E. Meilahn, 1995, Annals of epidemiology.

Sam Wieand, PhD

D. Sargent, J. Costantino, N. Wolmark, 2006 .

Thyroid function and perimenopausal lipid and weight changes: the Thyroid Study in Healthy Women (TSH-W).

L. Kuller, J. Costantino, E. Meilahn, 1997, Journal of women's health.

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

S. Paik, G. Tang, S. Shak, 2018, npj Breast Cancer.

Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies

D. Schaid, G. Jenkins, R. Weinshilboum, 2012, Genetic epidemiology.

The study of tamoxifen and raloxifene (STAR): Initial findings from the NSABP P-2 breast cancer prevention study.

W. McCaskill-Stevens, J. Costantino, D. Wickerham, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/ NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer

S. Paik, J. Costantino, C. Geyer, 2019 .

Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.

E. Perez, J. Costantino, C. Geyer, 2010, The New England journal of medicine.

Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

W. McCaskill-Stevens, J. Costantino, D. Wickerham, 2010, Journal of the National Cancer Institute. Monographs.

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

T. Julian, J. Costantino, N. Wolmark, 2016, The Lancet.

Association of tamoxifen and uterine sarcoma.

J. Bryant, J. Costantino, D. Wickerham, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.